Diagnostic and Therapeutic Potential of MicroRNAs in Lung Cancer

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2017 May 10

PMID 28486396

Citations 39

Authors

Kentaro Inamura

Affiliations

Soon will be listed here.

Abstract

Lung cancer is the leading cause of deaths resulting from cancer owing to late diagnosis and limited treatment intervention. MicroRNAs are short, non-coding RNA molecules that regulate gene expression post-transcriptionally by translational repression or target messenger RNA degradation. Accumulating evidence suggests various roles for microRNAs, including development and progression of lung cancers. Because microRNAs are degraded to a much lesser extent in formalin-fixed paraffin-embedded specimens and are present not only in tumor tissues but also in body fluids, there is an increased potential in microRNA analyses for cancer research. In this review, recent studies of microRNA are introduced and briefly summarized, with a focus on the association of microRNAs with histological subtypes, genetic driver alterations, therapeutically-targeted molecules, and carcinogens. The reported circulating microRNA signature for the early detection of lung cancer and the implications of microRNAs as the modulators of tumor immune response are also introduced.

Citing Articles

Circ_0004140 promotes lung adenocarcinoma progression by upregulating NOVA2 via sponging miR-330-5p.

Xia F, Xie M, He J, Cheng D Thorac Cancer. 2023; 14(35):3483-3494.

PMID: 37920146 PMC: 10719663. DOI: 10.1111/1759-7714.15141.

Construction of a New Immune-Related Competing Endogenous RNA Network with Prognostic Value in Lung Adenocarcinoma.

Liu L, Li J, Fan C, Wen M, Li C, Sun W Mol Biotechnol. 2023; 66(2):300-310.

PMID: 37118319 DOI: 10.1007/s12033-023-00754-7.

The importance microRNAs as a biomarker in lung cancer.

Canatan D, Sonmez Y, Yilmaz O, Coskun H, Sezgin Goksu S, Ucar S Acta Biomed. 2023; 94(1):e2023045.

PMID: 36786270 PMC: 9987486. DOI: 10.23750/abm.v94i1.13334.

Identification of the Key miRNAs and Genes Associated with the Regulation of Non-Small Cell Lung Cancer: A Network-Based Approach.

Shafat Z, Ahmed M, Almajhdi F, Hussain T, Parveen S, Ahmed A Genes (Basel). 2022; 13(7).

PMID: 35885958 PMC: 9317345. DOI: 10.3390/genes13071174.

circ_0000567/miR-421/ Axis Promotes the Migration and Invasion of Lung Adenocarcinoma and Is Associated with Prognosis.

Hong Y, Si J, Xiao B, Xiong Y, Dai C, Yang Y J Cancer. 2022; 13(5):1540-1552.

PMID: 35371319 PMC: 8965118. DOI: 10.7150/jca.60124.

References

Vaishnavi A, Capelletti M, Le A, Kako S, Butaney M, Ercan D . Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013; 19(11):1469-1472. PMC: 3823836. DOI: 10.1038/nm.3352. View

Hou J, Meng F, Chan L, Cho W, Wong S . Circulating Plasma MicroRNAs As Diagnostic Markers for NSCLC. Front Genet. 2016; 7:193. PMC: 5093122. DOI: 10.3389/fgene.2016.00193. View

Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H . ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features. Lung Cancer. 2014; 84(2):121-6. DOI: 10.1016/j.lungcan.2014.02.007. View

Nadal E, Zhong J, Lin J, Reddy R, Ramnath N, Orringer M . A MicroRNA cluster at 14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res. 2014; 20(12):3107-17. DOI: 10.1158/1078-0432.CCR-13-3348. View

Wozniak M, Scelo G, Muller D, Mukeria A, Zaridze D, Brennan P . Circulating MicroRNAs as Non-Invasive Biomarkers for Early Detection of Non-Small-Cell Lung Cancer. PLoS One. 2015; 10(5):e0125026. PMC: 4428831. DOI: 10.1371/journal.pone.0125026. View

Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M . EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008; 3(1):13-7. DOI: 10.1097/JTO.0b013e31815e8b60. View

Rothschild S . Targeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALK. Cancers (Basel). 2015; 7(2):930-49. PMC: 4491691. DOI: 10.3390/cancers7020816. View

Inamura K, Yokouchi Y, Kobayashi M, Sakakibara R, Ninomiya H, Subat S . Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. Lung Cancer. 2016; 103:44-51. DOI: 10.1016/j.lungcan.2016.11.013. View

10.

Tumeh P, Harview C, Yearley J, Shintaku I, Taylor E, Robert L . PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014; 515(7528):568-71. PMC: 4246418. DOI: 10.1038/nature13954. View

11.

Frixa T, Donzelli S, Blandino G . Oncogenic MicroRNAs: Key Players in Malignant Transformation. Cancers (Basel). 2015; 7(4):2466-85. PMC: 4695904. DOI: 10.3390/cancers7040904. View

12.

Yu Y, Zuo J, Tan Q, Thin K, Li P, Zhu M . Plasma miR-92a-2 as a biomarker for small cell lung cancer. Cancer Biomark. 2017; 18(3):319-327. DOI: 10.3233/CBM-160254. View

13.

Takahashi R, Miyazaki H, Ochiya T . The Roles of MicroRNAs in Breast Cancer. Cancers (Basel). 2015; 7(2):598-616. PMC: 4491673. DOI: 10.3390/cancers7020598. View

14.

Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M . Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res. 2014; 20(12):3087-93. PMC: 6329293. DOI: 10.1158/1078-0432.CCR-14-0107. View

15.

Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S . RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18(3):378-81. DOI: 10.1038/nm.2658. View

16.

Montani F, Marzi M, Dezi F, Dama E, Mary Carletti R, Bonizzi G . miR-Test: a blood test for lung cancer early detection. J Natl Cancer Inst. 2015; 107(6):djv063. DOI: 10.1093/jnci/djv063. View

17.

Han L, Wang W, Ding W, Zhang L . MiR-9 is involved in TGF-β1-induced lung cancer cell invasion and adhesion by targeting SOX7. J Cell Mol Med. 2017; 21(9):2000-2008. PMC: 5571535. DOI: 10.1111/jcmm.13120. View

18.

Cortez M, Ivan C, Valdecanas D, Wang X, Peltier H, Ye Y . PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst. 2015; 108(1). PMC: 4862407. DOI: 10.1093/jnci/djv303. View

19.

Li C, Lyu J, Meng Q . MiR-93 Promotes Tumorigenesis and Metastasis of Non-Small Cell Lung Cancer Cells by Activating the PI3K/Akt Pathway via Inhibition of //. J Cancer. 2017; 8(5):870-879. PMC: 5381176. DOI: 10.7150/jca.17958. View

20.

Ueda R, Kohanbash G, Sasaki K, Fujita M, Zhu X, Kastenhuber E . Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. Proc Natl Acad Sci U S A. 2009; 106(26):10746-51. PMC: 2705554. DOI: 10.1073/pnas.0811817106. View